62.77

2.73% -1.76

After Hours: 62.00 -0.77 -1.23%

Kiniksa Pharmaceuticals International Plc (KNSA)

Overview News Price History Option Chain Financials Discussions Forecast

Kiniksa Pharmaceuticals International Plc stock is traded at $62.77, with a volume of 629.88K. It is down -2.73% in the last 24 hours and up +29.64% over the past month. Kiniksa Pharmaceuticals International PLC is a clinical-stage biopharmaceutical company focused on discovering, acquiring, developing, and commercializing therapeutic medicines for patients suffering from debilitating cardiovascular diseases. The company's clinical-stage product candidates include Rilonacept, abiprubart, and Vixarelimab. Geographically, the company earns maximum revenue from United States.

Previous Close:

$64.53

Open:

$64.43

24h Volume:

629.88K

Relative Volume:

0.80

Market Cap:

$4.83B

Revenue:

$754.05M

Net Income/Loss:

$73.06M

P/E Ratio:

69.18

EPS:

0.9073

Net Cash Flow:

$164.23M

1W Performance:

+0.58%

1M Performance:

+29.64%

6M Performance:

+47.07%

1Y Performance:

+125.14%

1-Day Range:

$62.73

$65.16

1-Week Range:

$61.60

$65.16

52-Week Range:

$26.27

$65.16

Kiniksa Pharmaceuticals International Plc Stock (KNSA) Company Profile

Name

Kiniksa Pharmaceuticals International Plc

Sector

Healthcare (1100)

Industry

Drug Manufacturers - Specialty & Generic (86)

Phone

(781) 431-9100

Address

105 PICCADILLY, SECOND FLOOR, LONDON

Employee

366

Twitter

@kiniksa

Next Earnings Date

2026-08-04

Latest SEC Filings

KNSA's Discussions on Twitter

Compare KNSA vs TAK, HLN, TEVA, ZTS, UTHR

Stocks	Price	Market Cap	Revenue	Net Income	Cash Flow	EPS
KNSA Kiniksa Pharmaceuticals International Plc	62.77	4.92B	754.05M	73.06M	164.23M	0.9073
TAK Takeda Pharmaceutical Co Adr	16.89	50.65B	29.91B	1.30B	3.49B	0.4056
HLN Haleon Plc Adr	9.72	41.09B	14.54B	2.22B	2.58B	0.4871
TEVA Teva Pharmaceutical Industries Ltd Adr	35.29	39.45B	17.53B	1.58B	444.18M	1.3457
ZTS Zoetis Inc	75.42	30.13B	9.51B	2.64B	2.14B	6.0361
UTHR United Therapeutics Corp	547.25	23.00B	3.17B	1.29B	1.01B	27.09

Kiniksa Pharmaceuticals International Plc Stock (KNSA) Upgrades & Downgrades

Date	Action	Analyst	Rating Change
Feb-19-26	Initiated	Canaccord Genuity	Buy
Sep-29-25	Initiated	TD Cowen	Buy
Mar-13-25	Initiated	Citigroup	Buy
Sep-13-24	Initiated	Jefferies	Buy
May-03-24	Initiated	Wells Fargo	Overweight
Jun-29-20	Reiterated	BofA Securities	Buy
Apr-01-20	Initiated	BofA/Merrill	Buy
Mar-11-19	Initiated	Barclays	Overweight
Dec-12-18	Reiterated	Wedbush	Outperform
Jun-19-18	Initiated	JMP Securities	Mkt Outperform

View All

Kiniksa Pharmaceuticals International Plc Stock (KNSA) Latest News

Jul 02, 2026

Kiniksa Pharmaceuticals Hits New 52-Week High of USD 59.89 - MarketsMojo

Jul 02, 2026

Jul 01, 2026

Kiniksa Pharmaceuticals Hits New 52-Week High of USD 63.77 - MarketsMojo

Jul 01, 2026

Peregrine Capital Management LLC Sells 29,550 Shares of Kiniksa Pharmaceuticals International, plc $KNSA - MarketBeat

Jul 01, 2026

Inspire Investing LLC Makes New $1.70 Million Investment in Kiniksa Pharmaceuticals International, plc $KNSA - MarketBeat

Jul 01, 2026

Pictet Asset Management Holding SA Sells 164,232 Shares of Kiniksa Pharmaceuticals International, plc $KNSA - MarketBeat

Jul 01, 2026

Jun 30, 2026

What Makes Kiniksa Pharmaceuticals International, plc (KNSA) a Strong Momentum Stock: Buy Now? - Yahoo Finance

Jun 30, 2026